#United States #New York #Securities #Levi Korsinsky #Zoetis

In a significant development for shareholders of Zoetis Inc. (NYSE: ZTS), the law firm Levi & Korsinsky, LLP, is urging those who acquired securities of the company between January 14, 2025, and May 6, 2026, to take immediate action in light of a looming deadline for a securities class action. This class action has arisen due to substantial declines in the company's stock prices following a series of revelations that undermined prior claims concerning the strength of its flagship products.

Recent Events Stack Up Against Zoetis

During the specified class period, Zoetis shares experienced a staggering cumulative loss of more than 42%. This downturn was triggered by four key disclosures that highlighted deteriorating performance metrics and increased market pressures that investors were not previously made aware of. These events unfolded as follows:

• - On January 14, 2025, Zoetis presented what appeared to be an optimistic view at the JP Morgan Healthcare Conference, asserting that their Companion Animal portfolio could maintain durable growth. They projected that their dermatology market could reach $2.5 billion by 2028, coupled with highlighting Librela's success beginning as 'the best launch ever in animal health.' At this time, investors felt reassured about the company's trajectory.

• - However, on August 5, 2025, reality began to shift when Zoetis disclosed second-quarter results indicating weaknesses within its pain franchise. Analysts noted a downturn in demand trends, leading to a significant drop in stock prices as the market recalibrated its expectations based on earlier management assertions. The ZTS stock fell by 3.8%, closing at $146.12.

• - By November 4, 2025, further troubling signals emerged. The release of third-quarter results illustrated a continued slowdown in growth, leading to a revised full-year sales outlook. Market reactions were immediate and severe, with a stock price decrease of 13.8% bringing the shares down to $124.46.

• - The most severe hit came on May 7, 2026, when first-quarter results revealed sharp declines across all Companion Animal business segments. The Company admitted to losing market share and acknowledged negative market dynamics in the dermatology sector. This disclosure resulted in an alarming drop of 21.5%, with shares closing at $87.31.

Legal Actions and Next Steps

The lead plaintiff deadline for this class action is set for July 27, 2026. Shareholders affected during the class period are encouraged to reach out to Levi & Korsinsky to assess their claim eligibility. Notably, even investors who have already sold their shares during this period can still recover losses as eligibility hinges on purchase timing rather than current ownership.

Joseph E. Levi, Esq., one of the leading attorneys managing this action, emphasizes the critical nature of timely disclosures in maintaining market fairness and efficiency. He notes, 'The chronology in this case raises important questions about why investors were repeatedly reassured about franchise strength while competitive and safety headwinds were intensifying quarter after quarter.'

Individuals seeking to validate their eligibility to recover damages are advised to compile relevant brokerage records, including purchase dates and share quantities. Levi & Korsinsky offers a no-commitment consultation to evaluate potential claims.

Participating in this legal action incurs no upfront costs, as securities class actions proceed on a contingency fee basis. Shareholders are urged to take action promptly, considering how the circumstances surrounding Zoetis Inc. have evolved dramatically since early 2025.

For more information or assistance, interested parties can contact Joseph E. Levi, Esq. at (212) 363-7500, or email inquiries to [email protected]. It is crucial for investors to act swiftly to safeguard their interests and potentially recuperate losses sustained in their investments with Zoetis Inc.